Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care—Registry data from an outcomes research project of the German Testicular Cancer Study Group

Seidel, Christoph; Oechsle, Karin; Lorch, Anja; Dieing, Annette; Hentrich, Marcus; Hornig, Mareike; Grünwald, Viktor; Cathomas, Richard; Meiler, Johannes; Wit, Maike de; Bokemeyer, Carsten

doi:10.1016/j.urolonc.2015.11.007

Cited by 30 publications

(12 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The recommended third-line palliative chemotherapy options for patients with intensively pretreated, cisplatin-resistant, or refractory GCTs are combinations of gemcitabine with paclitaxel and/or oxaliplatin, [121][122][123][124][125][126][127] or oral etoposide. 128 The recommendation for gemcitabine and oxaliplatin (GEMOX) is based on data from phase II studies investigating the efficacy and toxicity of GEMOX in patients with relapsed or cisplatin-resistant GCTs.…”

Section: Third-line Therapymentioning

confidence: 99%

“…A second study reported similar results. 127 Additionally, high-dose single-agent oral etoposide was shown to be effective in a phase II study involving patients who had previous treatment with cisplatin/etoposide combination regimens. 128 Pembrolizumab, an anti-PD-1 antibody, was approved by the FDA for the treatment of patients with unresectable or metastatic MSI-H/dMMR solid tumors that have progressed after previous treatment and who have no satisfactory alternative treatment options.…”

Section: Third-line Therapymentioning

confidence: 99%

See 1 more Smart Citation

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Gilligan

Lin

Aggarwal

et al. 2019

Journal of the National Comprehensive Cancer Network

196

233

View full text Add to dashboard Cite

Testicular cancer is relatively uncommon and accounts for ,1% of all male tumors. However, it is the most common solid tumor in men between the ages of 20 and 34 years, and the global incidence has been steadily rising over the past several decades. Several risk factors for testicular cancer have been identified, including personal or family history of testicular cancer and cryptorchidism. Testicular germ cell tumors (GCTs) comprise 95% of malignant tumors arising in the testes and are categorized into 2 main histologic subtypes: seminoma and nonseminoma. Although nonseminoma is the more clinically aggressive tumor subtype, 5-year survival rates exceed 70% with current treatment options, even in patients with advanced or metastatic disease. Radical inguinal orchiectomy is the primary treatment for most patients with testicular GCTs. Postorchiectomy management is dictated by stage, histology, and risk classification; treatment options for nonseminoma include surveillance, systemic therapy, and nervesparing retroperitoneal lymph node dissection. Although rarely occurring, prognosis for patients with brain metastases remains poor, with .50% of patients dying within 1 year of diagnosis. This selection from the NCCN Guidelines for Testicular Cancer focuses on recommendations for the management of adult patients with nonseminomatous GCTs.

show abstract

Section: Third-line Therapymentioning

confidence: 99%

Section: Third-line Therapymentioning

confidence: 99%

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Gilligan

Lin

Aggarwal

et al. 2019

Journal of the National Comprehensive Cancer Network

196

233

View full text Add to dashboard Cite

show abstract

“…The German Testicular Cancer Study Group (GTCSG) reported, in a phase II trial, long-term overall survival >2 years in 17 % of heavily pretreated cisplatin-refractory or cisplatinrelapsed patients receiving the GOP regimen [68]. Seidel et al published data of a new retrospective multicenter registry study on the efficacy of GOP in daily practice and reported similar rates [69]. These dismal survival rates urge the need of more effective drugs and opened the door to investigate targeted therapy in patients with relapsed or refractory TGCTs.…”

Section: Clinical Trials Using Targeted Therapies In Relapsed or Refrmentioning

confidence: 99%

Will Testicular Germ Cell Tumors Remain Untargetable?

et al. 2016

View full text Add to dashboard Cite

Testicular Germ cell tumors (TGCT) represent the most common solid tumors affecting young men. They constitute a distinct entity because of their embryonic origin and their unique biological behavior. Recently, new preclinical data on genetic and epigenetic susceptibility profiles, biological signaling machinery as well as on molecular patterns of tumors and pathways of pathogenesis helped to elucidate the pathogenesis and the differentiation of TGCTs and to understand the mechanisms behind the development of resistance to treatment. In the present work, we have reviewed new clues to the development, differentiation and progression of TGCTs. We focus on the most important epigenetic and molecular biomarkers, and discussed their diagnostic and prognostic accuracy compared to the currently used biomarkers. The mechanisms underlying the development of resistance to cisplatin and commonly used chemotherapeutic agents are also discussed in detail. Finally, we summarize failed and ongoing clinical trials using targeted therapies in resistant TGCTs, and analyze the potential of new targeted therapies.

show abstract

“…Combinations of drugs with single-agent activity result in higher response rates compared to using single-agent treatment alone. The triple combination of gemcitabine, oxaliplatin and paclitaxel (GOP) reported the highest response rates so far with more than 50% objective responses and even few long-term remissions ( Table 2) [22][23][24][25]. Doublet combinations of these drugs may also provide favorable responses ranging from 4% to 46% (Table 3) [26][27][28][29][30][31].…”

Section: Combination Chemotherapymentioning

confidence: 99%

Palliative treatment of germ cell cancer

Oing

Giannatempo

Honecker

et al. 2018

Cancer Treatment Reviews

Self Cite

View full text Add to dashboard Cite

A B S T R A C TMost patients with metastatic germ-cell cancer (GCC) can be cured by cisplatin-based combination chemotherapy. Yet, about 10-15% of metastatic GCC patients will eventually die of their disease. This narrative review focuses on treatment options when cure is no longer realistic. Single agent chemotherapySingle agent activity has been reported for paclitaxel [10][11][12][13][14], gemcitabine [15,16], oxaliplatin [17,18], oral etoposide [19], ifosfamide [20], and oral temozolomide [21] mainly in small phase I/II trials in patients with cisplatin-refractory disease. Responses were mainly partial remissions or disease stabilizations. However, sequential single agent treatment is an appropriate option in addition to best-supportivehttps://doi.

show abstract

Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care—Registry data from an outcomes research project of the German Testicular Cancer Study Group

Cited by 30 publications

References 17 publications

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Will Testicular Germ Cell Tumors Remain Untargetable?

Palliative treatment of germ cell cancer

Contact Info

Product

Resources

About